Amundi Kymera Therapeutics, Inc. Transaction History

Amundi

$275 Billion
Q4 2024

A detailed history of Amundi transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Amundi holds 19 shares of KYMR stock, worth $699. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$699

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 07, 2025	BUY	$39.06 - $51.84 $742 - $984	19 New	19 $0
Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $32,133 - $50,770	1,642 New	1,642 $40,000

Others Institutions Holding KYMR

# of Institutions

186

Shares Held

65.5M

Call Options Held

49.6K

Put Options Held

17K

Price T Rowe Associates Inc Baltimore, MD

6.87M
Shares

$253 Million
0.03% of portfolio
Baker Bros. Advisors LP New York, NY

6M
Shares

$221 Million
2.67% of portfolio
Wellington Management Group LLP Boston, MA

5.31M
Shares

$195 Million
0.04% of portfolio
Bvf Inc San Francisco, CA

5.16M
Shares

$190 Million
7.77% of portfolio
Avoro Capital Advisors LLC New York, NY

5.15M
Shares

$190 Million
3.02% of portfolio

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.01B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account